ABSTRACT
LOWERING LDL CHOLESTEROL BEYOND HMG-COA REDUCTASE INHIBITION Circulating cholesterol, VLDL and LDL are derived from two sources: endogenous synthesis via liver and exogenous absorption via alimentary tract. Numerous enzymes, transporters, and lipoprotein transfer pathways are involved, providing opportunities for pharmacological interventions beyond inhibition of HMG-COA reductase (Fig. 37.2).
